Dublin, March 19, 2025 (GLOBE NEWSWIRE) — The “Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report by Linker (Cleavable, Non-Cleavable), Condition (Myeloma, Lymphoma, Breast Cancer), and Region with Growth Forecasts, 2025-2030” has been added to ResearchAndMarkets.com’s offering.
The Antibody Drug Conjugates Contract Manufacturing Market was valued at USD 8.87 billion in 2024, and is projected to reach USD 16.55 billion by 2030, rising at a CAGR of 10.99%. The factors driving the industry growth include the complex nature of antibody drug conjugates (ADCs) contributing to the demand for contract manufacturing, the increasing number of research on antibody therapies, and the rise in cancer incidence.
Antibody Drug Conjugates Contract Manufacturing Market Report Highlights
- Based on condition, the market includes myeloma, lymphoma, breast cancer and others. The myeloma segment led the market with the largest revenue share of 49.61% in 2024. The lymphoma segment is anticipated to witness the fastest CAGR during the forecast period.
- Based on linker, the market is segmented into cleavable linkers and non-cleavable linkers. The cleavable linkers segment led the market with the largest revenue share of 56.1% in 2024.
- The antibody drug conjugates contract manufacturing market in North America is expected to witness the fastest CAGR over the forecast period.
- Asia Pacific antibody drug conjugates contract manufacturing market dominated the market with the largest revenue share of 40.93% in 2024. The regional growth is primarily owing to supportive regulatory reforms, especially in countries such as India & China, and low-cost labor.
This report addresses:
- Market intelligence to enable effective decision-making.
- Market estimates and forecasts from 2018 to 2030.
- Growth opportunities and trend analyses.
- Segment and regional revenue forecasts for market assessment.
- Competition strategy and market share analysis.
- Product innovation listings for you to stay ahead of the curve.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 100 |
| Forecast Period | 2024-2030 |
| Estimated Market Value (USD) in 2024 | $8.87 Billion |
| Forecasted Market Value (USD) by 2030 | $16.55 Billion |
| Compound Annual Growth Rate | 10.9% |
| Regions Covered | Global |
Key Topics Covered
Chapter 1. Research Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Incidence of Cancer
3.2.1.2. High Cost of Manufacturing ADC and Challenges Associated With Manufacturing Contributing to the Demand for Contract Manufacturing
3.2.1.3. Increasing R&D Activities on ADCs
3.2.2. Market Restraint Analysis
3.2.2.1. Quality Issues While Outsourcing
3.2.2.2. Limited Outsourcing Opted by Big Biopharma Companies
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Industry Ecosystem Analysis
3.6. Market Analysis Tools
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTEL Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Condition Estimates & Trend Analysis
4.1. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition: Segment Dashboard
4.2. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition: Movement Analysis
4.3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates & Forecasts, by Condition, 2018-2030 (USD Million)
4.4. Myeloma
4.5. Lymphoma
4.6. Breast Cancer
4.7. Others
Chapter 5. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Linker Estimates & Trend Analysis
5.1. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker: Segment Dashboard
5.2. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker: Movement Analysis
5.3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates & Forecasts, by Linker, 2018-2030 (USD Million)
5.4. Cleavable Linker
5.5. Non-Cleavable Linker
Chapter 6. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. North America
6.5. Europe
6.6. Asia-Pacific
6.7. Latin America
6.8. MEA
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.1.1. Market Leaders
7.1.2. Emerging Players
7.2. Company Market Share/Assessment Analysis, 2024
7.3. Company Profiles
7.3.1. Sterling
7.3.2. Recipharm AB
7.3.3. Lonza
7.3.4. Catalent Inc.
7.3.5. Sartorius AG
7.3.6. Wuxi Biologics
7.3.7. Samsung Biologics
7.3.8. Piramal Group (Piramal Pharma Solutions)
7.3.9. AbbVie Inc. (AbbVie Contract Manufacturing)
7.3.10. Merck KGaA
For more information about this report visit https://www.researchandmarkets.com/r/irazqs
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Antibody Drug Conjugates Contract Manufacturing Market
